Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.

Purpose: Thromboembolism is a common adverse event in women treated with tamoxifen (TAM) for breast cancer. The risk in male breast cancer patients is poorly investigated. We aimed to examine the risk of thrombotic events after TAM in male breast cancer patients.